Antibody derived peptides for detection of Ebola virus glycoprotein

Luis Mario Rodríguez-Martínez; Alan Roberto Marquez-Ipiña; Felipe López-Pacheco; Roberto Pérez-Chavarría; Juan Carlos González-Vázquez; Everardo González-González; Grissel Trujillo-De Santiago; César Alejandro Ponce Ponce De León; Yu Shrike Zhang; Mehmet Remzi Dokmeci; Ali Khademhosseini; Mario Moisés Alvarez

doi:10.1371/journal.pone.0135859

Antibody derived peptides for detection of Ebola virus glycoprotein

Luis Mario Rodríguez-Martínez, Alan Roberto Marquez-Ipiña, Felipe López-Pacheco, Roberto Pérez-Chavarría, Juan Carlos González-Vázquez, Everardo González-González, Grissel Trujillo-De Santiago, César Alejandro Ponce Ponce De León, Yu Shrike Zhang, Mehmet Remzi Dokmeci, Ali Khademhosseini, Mario Moisés Alvarez

Research output: Contribution to journal › Article › peer-review

12 Citations (Scopus)

Abstract

Background: Current Ebola virus (EBOV) detection methods are costly and impractical for epidemic scenarios. Different immune-based assays have been reported for the detection and quantification of Ebola virus (EBOV) proteins. In particular, several monoclonal antibodies (mAbs) have been described that bind the capsid glycoprotein (GP) of EBOV GP. However, the currently available platforms for the design and production of full-length mAbs are cumbersome and costly. The use of antibody fragments, rather than full-length antibodies, might represent a cost-effective alternative for the development of diagnostic and possibly even therapeutic alternatives for EBOV. Methods/principal findings: We report the design and expression of three recombinant anti-GP mAb fragments in Escherichia coli cultures. These fragments contained the heavy and light variable portions of the three well-studied anti-GP full-length mAbs 13C6, 13F6, and KZ52, and are consequently named scFv-13C6, scFv-13F6, and Fab-KZ52, respectively. All three fragments exhibited specific anti-GP binding activity in ELISA experiments comparable to that of fulllength anti-GP antibodies (i.e., the same order of magnitude) and they are easily and economically produced in bacterial cultures. Conclusion/significance: Antibody fragments might represent a useful, effective, and low cost alternative to full-length antibodies in Ebola related capture and diagnostics applications.

Original language	English
Article number	e0135859
Pages (from-to)	e0135859
Journal	PLoS One
Volume	10
Issue number	10
DOIs	https://doi.org/10.1371/journal.pone.0135859
Publication status	Published - 21 Oct 2015
Externally published	Yes

Bibliographical note

Funding Information:
MMA gratefully acknowledge the institutional funding received from Tecnológico de Monterrey (seed funding to Strategic Research Groups, 2015) and funding provided from CONACyT (Consejo Nacional de Ciencia y Tecnología, México) in the form of Scholarships to GTdS, ARMI, EGG, and RPCh. MMA, GTdS and AK acknowledge funding from MIT International Science and Technology Initiatives (MISTI). GTdS acknowledges funding form Fundación México en Harvard. AK, SY, and MD acknowledge funding from the National Science Foundation (EFRI–1240443), IMMODGEL (602694), and the National Institutes of Health (EB012597, AR057837, DE021468, HL099073, AI105024, AR063745).

Publisher Copyright:
© 2015 Rodríguez-Martínez et al.This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

All Science Journal Classification (ASJC) codes

General

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1371/journal.pone.0135859

Cite this

Rodríguez-Martínez, L. M., Marquez-Ipiña, A. R., López-Pacheco, F., Pérez-Chavarría, R., González-Vázquez, J. C., González-González, E., Trujillo-De Santiago, G., De León, C. A. P. P., Zhang, Y. S., Dokmeci, M. R., Khademhosseini, A., & Alvarez, M. M. (2015). Antibody derived peptides for detection of Ebola virus glycoprotein. PLoS One, 10(10), e0135859. Article e0135859. https://doi.org/10.1371/journal.pone.0135859

@article{7e90920b1cc74d688e307efd49644b52,

title = "Antibody derived peptides for detection of Ebola virus glycoprotein",

abstract = "Background: Current Ebola virus (EBOV) detection methods are costly and impractical for epidemic scenarios. Different immune-based assays have been reported for the detection and quantification of Ebola virus (EBOV) proteins. In particular, several monoclonal antibodies (mAbs) have been described that bind the capsid glycoprotein (GP) of EBOV GP. However, the currently available platforms for the design and production of full-length mAbs are cumbersome and costly. The use of antibody fragments, rather than full-length antibodies, might represent a cost-effective alternative for the development of diagnostic and possibly even therapeutic alternatives for EBOV. Methods/principal findings: We report the design and expression of three recombinant anti-GP mAb fragments in Escherichia coli cultures. These fragments contained the heavy and light variable portions of the three well-studied anti-GP full-length mAbs 13C6, 13F6, and KZ52, and are consequently named scFv-13C6, scFv-13F6, and Fab-KZ52, respectively. All three fragments exhibited specific anti-GP binding activity in ELISA experiments comparable to that of fulllength anti-GP antibodies (i.e., the same order of magnitude) and they are easily and economically produced in bacterial cultures. Conclusion/significance: Antibody fragments might represent a useful, effective, and low cost alternative to full-length antibodies in Ebola related capture and diagnostics applications.",

author = "Rodr{\'i}guez-Mart{\'i}nez, {Luis Mario} and Marquez-Ipi{\~n}a, {Alan Roberto} and Felipe L{\'o}pez-Pacheco and Roberto P{\'e}rez-Chavarr{\'i}a and Gonz{\'a}lez-V{\'a}zquez, {Juan Carlos} and Everardo Gonz{\'a}lez-Gonz{\'a}lez and {Trujillo-De Santiago}, Grissel and {De Le{\'o}n}, {C{\'e}sar Alejandro Ponce Ponce} and Zhang, {Yu Shrike} and Dokmeci, {Mehmet Remzi} and Ali Khademhosseini and Alvarez, {Mario Mois{\'e}s}",

note = "Funding Information: MMA gratefully acknowledge the institutional funding received from Tecnol{\'o}gico de Monterrey (seed funding to Strategic Research Groups, 2015) and funding provided from CONACyT (Consejo Nacional de Ciencia y Tecnolog{\'i}a, M{\'e}xico) in the form of Scholarships to GTdS, ARMI, EGG, and RPCh. MMA, GTdS and AK acknowledge funding from MIT International Science and Technology Initiatives (MISTI). GTdS acknowledges funding form Fundaci{\'o}n M{\'e}xico en Harvard. AK, SY, and MD acknowledge funding from the National Science Foundation (EFRI–1240443), IMMODGEL (602694), and the National Institutes of Health (EB012597, AR057837, DE021468, HL099073, AI105024, AR063745). Publisher Copyright: {\textcopyright} 2015 Rodr{\'i}guez-Mart{\'i}nez et al.This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.",

year = "2015",

month = oct,

day = "21",

doi = "10.1371/journal.pone.0135859",

language = "English",

volume = "10",

pages = "e0135859",

journal = "PLoS One",

issn = "1932-6203",

publisher = "Public Library of Science",

number = "10",

}

Rodríguez-Martínez, LM, Marquez-Ipiña, AR, López-Pacheco, F, Pérez-Chavarría, R, González-Vázquez, JC, González-González, E, Trujillo-De Santiago, G, De León, CAPP, Zhang, YS, Dokmeci, MR, Khademhosseini, A & Alvarez, MM 2015, 'Antibody derived peptides for detection of Ebola virus glycoprotein', PLoS One, vol. 10, no. 10, e0135859, pp. e0135859. https://doi.org/10.1371/journal.pone.0135859

TY - JOUR

T1 - Antibody derived peptides for detection of Ebola virus glycoprotein

AU - Rodríguez-Martínez, Luis Mario

AU - Marquez-Ipiña, Alan Roberto

AU - López-Pacheco, Felipe

AU - Pérez-Chavarría, Roberto

AU - González-Vázquez, Juan Carlos

AU - González-González, Everardo

AU - Trujillo-De Santiago, Grissel

AU - De León, César Alejandro Ponce Ponce

AU - Zhang, Yu Shrike

AU - Dokmeci, Mehmet Remzi

AU - Khademhosseini, Ali

AU - Alvarez, Mario Moisés

N1 - Funding Information: MMA gratefully acknowledge the institutional funding received from Tecnológico de Monterrey (seed funding to Strategic Research Groups, 2015) and funding provided from CONACyT (Consejo Nacional de Ciencia y Tecnología, México) in the form of Scholarships to GTdS, ARMI, EGG, and RPCh. MMA, GTdS and AK acknowledge funding from MIT International Science and Technology Initiatives (MISTI). GTdS acknowledges funding form Fundación México en Harvard. AK, SY, and MD acknowledge funding from the National Science Foundation (EFRI–1240443), IMMODGEL (602694), and the National Institutes of Health (EB012597, AR057837, DE021468, HL099073, AI105024, AR063745). Publisher Copyright: © 2015 Rodríguez-Martínez et al.This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

PY - 2015/10/21

Y1 - 2015/10/21

N2 - Background: Current Ebola virus (EBOV) detection methods are costly and impractical for epidemic scenarios. Different immune-based assays have been reported for the detection and quantification of Ebola virus (EBOV) proteins. In particular, several monoclonal antibodies (mAbs) have been described that bind the capsid glycoprotein (GP) of EBOV GP. However, the currently available platforms for the design and production of full-length mAbs are cumbersome and costly. The use of antibody fragments, rather than full-length antibodies, might represent a cost-effective alternative for the development of diagnostic and possibly even therapeutic alternatives for EBOV. Methods/principal findings: We report the design and expression of three recombinant anti-GP mAb fragments in Escherichia coli cultures. These fragments contained the heavy and light variable portions of the three well-studied anti-GP full-length mAbs 13C6, 13F6, and KZ52, and are consequently named scFv-13C6, scFv-13F6, and Fab-KZ52, respectively. All three fragments exhibited specific anti-GP binding activity in ELISA experiments comparable to that of fulllength anti-GP antibodies (i.e., the same order of magnitude) and they are easily and economically produced in bacterial cultures. Conclusion/significance: Antibody fragments might represent a useful, effective, and low cost alternative to full-length antibodies in Ebola related capture and diagnostics applications.

AB - Background: Current Ebola virus (EBOV) detection methods are costly and impractical for epidemic scenarios. Different immune-based assays have been reported for the detection and quantification of Ebola virus (EBOV) proteins. In particular, several monoclonal antibodies (mAbs) have been described that bind the capsid glycoprotein (GP) of EBOV GP. However, the currently available platforms for the design and production of full-length mAbs are cumbersome and costly. The use of antibody fragments, rather than full-length antibodies, might represent a cost-effective alternative for the development of diagnostic and possibly even therapeutic alternatives for EBOV. Methods/principal findings: We report the design and expression of three recombinant anti-GP mAb fragments in Escherichia coli cultures. These fragments contained the heavy and light variable portions of the three well-studied anti-GP full-length mAbs 13C6, 13F6, and KZ52, and are consequently named scFv-13C6, scFv-13F6, and Fab-KZ52, respectively. All three fragments exhibited specific anti-GP binding activity in ELISA experiments comparable to that of fulllength anti-GP antibodies (i.e., the same order of magnitude) and they are easily and economically produced in bacterial cultures. Conclusion/significance: Antibody fragments might represent a useful, effective, and low cost alternative to full-length antibodies in Ebola related capture and diagnostics applications.

UR - http://www.scopus.com/inward/record.url?scp=84949522402&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84949522402&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0135859

DO - 10.1371/journal.pone.0135859

M3 - Article

C2 - 26489048

AN - SCOPUS:84949522402

SN - 1932-6203

VL - 10

SP - e0135859

JO - PLoS One

JF - PLoS One

IS - 10

M1 - e0135859

ER -

Antibody derived peptides for detection of Ebola virus glycoprotein

Abstract

Bibliographical note

All Science Journal Classification (ASJC) codes

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this